Najit Technologies, Inc.

This early-stage study tested a new, inactivated yellow fever vaccine in healthy adults to see if it was safe and if it could trigger a protective immune response. Twenty-six participants received either the vaccine or a placebo in two doses, one month apart. The main goal was to…

This early-stage trial tested a new vaccine designed to protect against chikungunya virus infection. It involved 48 healthy adults to check if the vaccine was safe and if it successfully triggered an immune response. Participants received two shots of either the vaccine or a plac…